Diagnosis and treatment of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituxi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2012-01-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1427 |
| _version_ | 1811194082613002240 |
|---|---|
| author | Ulrich J. M. Mey Felicitas Hitz Andreas Lohri Stefanie Pederiva Christian Taverna Alexander Tzankov Oliver Meier Karen Yeow Christoph Renner |
| author_facet | Ulrich J. M. Mey Felicitas Hitz Andreas Lohri Stefanie Pederiva Christian Taverna Alexander Tzankov Oliver Meier Karen Yeow Christoph Renner |
| author_sort | Ulrich J. M. Mey |
| collection | DOAJ |
| description |
Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), are currently the treatment backbone. Despite remarkable progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subsets of patients, including the elderly and very elderly and those with highly aggressive disease. This review outlines some of the current treatment strategies for DLBCL and discusses the main issues that affect clinical practice.
aaIPI = age-adjusted International Prognostic Index; ABC = activated B-cell – like; ACVBP = doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone; ASCO = American Society of Clinical Oncology; BCCA = British Columbia Cancer Agency; CALGB = Cancer and Leukaemia Group B; CEPP = cyclophosphamide, etoposide, procarbazine and prednisone; CHOEP = cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone; CNS = central nervous system; CORAL = Collaborative Trial in Relapsed Aggressive Lymphoma; CR = complete response; CT = computerised tomography; DFS = disease-free survival; DLBCL = diffuse large B-cell lymphoma; DSHNHL = German High-Grade Non-Hodgkin's Lymphoma Study Group; EFS = event-free survival; EORTC = European Organization for Research and Treatment of Cancer; ESHAP = etoposide, solumedrol, high-dose cytarabine and platinum; EPOCH = etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ESMO = European Society for Medical Oncology; FIL = Italian Lymphoma Foundation; FISH = fluorescence in-situ hybridisation; GCB = germinal centre B-cell – like; G-CSF = granulocyte colony-stimulating factor; GELA = Groupe d'Etude des Lymphomes de l'Adulte; HDT = high dose therapy; HIV = human immunodeficiency virus; ICE = ifosfamide, carboplatin and etoposide; IFRT = involved-field radiation therapy; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MInT = MabThera International Trial; NCCN = National Comprehensive Cancer Network; NHL = Non-Hodgkin’s lymphoma; NOS = not otherwise specified; OS = overall survival; PET = positron emission tomography; PMBL = primary mediastinal B-cell lymphoma; PFS = progression-free survival; R = rituximab; RICOVER-60 = Rituximab with CHOP over age 60 years; SCT = stem cell transplantation; SAKK = Schweizerische Arbeitsgruppe für Klinische Krebsforschung; SWOG = Southwest Oncology Group; WHO = World Health Organisation.
|
| first_indexed | 2024-04-12T00:20:11Z |
| format | Article |
| id | doaj.art-60c2c513282e46599040739cecb8864b |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2024-04-12T00:20:11Z |
| publishDate | 2012-01-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-60c2c513282e46599040739cecb8864b2022-12-22T03:55:44ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972012-01-01142050610.4414/smw.2012.13511Diagnosis and treatment of diffuse large B-cell lymphomaUlrich J. M. MeyFelicitas HitzAndreas LohriStefanie PederivaChristian TavernaAlexander TzankovOliver MeierKaren YeowChristoph Renner Diffuse large B-cell lymphoma (DLBCL) is the most frequently-occurring type of malignant lymphoma in the Western world. It has an aggressive natural history, with a median survival of less than one year if left untreated. Immunochemotherapy regimens, consisting of the anti-CD20 antibody rituximab typically in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), are currently the treatment backbone. Despite remarkable progress in improving patient survival, clinical outcomes are still unsatisfactory for certain subsets of patients, including the elderly and very elderly and those with highly aggressive disease. This review outlines some of the current treatment strategies for DLBCL and discusses the main issues that affect clinical practice. aaIPI = age-adjusted International Prognostic Index; ABC = activated B-cell – like; ACVBP = doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone; ASCO = American Society of Clinical Oncology; BCCA = British Columbia Cancer Agency; CALGB = Cancer and Leukaemia Group B; CEPP = cyclophosphamide, etoposide, procarbazine and prednisone; CHOEP = cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone; CHOP = cyclophosphamide, doxorubicin, vincristine and prednisone; CNS = central nervous system; CORAL = Collaborative Trial in Relapsed Aggressive Lymphoma; CR = complete response; CT = computerised tomography; DFS = disease-free survival; DLBCL = diffuse large B-cell lymphoma; DSHNHL = German High-Grade Non-Hodgkin's Lymphoma Study Group; EFS = event-free survival; EORTC = European Organization for Research and Treatment of Cancer; ESHAP = etoposide, solumedrol, high-dose cytarabine and platinum; EPOCH = etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ESMO = European Society for Medical Oncology; FIL = Italian Lymphoma Foundation; FISH = fluorescence in-situ hybridisation; GCB = germinal centre B-cell – like; G-CSF = granulocyte colony-stimulating factor; GELA = Groupe d'Etude des Lymphomes de l'Adulte; HDT = high dose therapy; HIV = human immunodeficiency virus; ICE = ifosfamide, carboplatin and etoposide; IFRT = involved-field radiation therapy; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MInT = MabThera International Trial; NCCN = National Comprehensive Cancer Network; NHL = Non-Hodgkin’s lymphoma; NOS = not otherwise specified; OS = overall survival; PET = positron emission tomography; PMBL = primary mediastinal B-cell lymphoma; PFS = progression-free survival; R = rituximab; RICOVER-60 = Rituximab with CHOP over age 60 years; SCT = stem cell transplantation; SAKK = Schweizerische Arbeitsgruppe für Klinische Krebsforschung; SWOG = Southwest Oncology Group; WHO = World Health Organisation. https://www.smw.ch/index.php/smw/article/view/1427chemotherapyDLBCLfirst-line treatmentfollow-upmaintenance treatmentrelapsed/refractory disease |
| spellingShingle | Ulrich J. M. Mey Felicitas Hitz Andreas Lohri Stefanie Pederiva Christian Taverna Alexander Tzankov Oliver Meier Karen Yeow Christoph Renner Diagnosis and treatment of diffuse large B-cell lymphoma Swiss Medical Weekly chemotherapy DLBCL first-line treatment follow-up maintenance treatment relapsed/refractory disease |
| title | Diagnosis and treatment of diffuse large B-cell lymphoma |
| title_full | Diagnosis and treatment of diffuse large B-cell lymphoma |
| title_fullStr | Diagnosis and treatment of diffuse large B-cell lymphoma |
| title_full_unstemmed | Diagnosis and treatment of diffuse large B-cell lymphoma |
| title_short | Diagnosis and treatment of diffuse large B-cell lymphoma |
| title_sort | diagnosis and treatment of diffuse large b cell lymphoma |
| topic | chemotherapy DLBCL first-line treatment follow-up maintenance treatment relapsed/refractory disease |
| url | https://www.smw.ch/index.php/smw/article/view/1427 |
| work_keys_str_mv | AT ulrichjmmey diagnosisandtreatmentofdiffuselargebcelllymphoma AT felicitashitz diagnosisandtreatmentofdiffuselargebcelllymphoma AT andreaslohri diagnosisandtreatmentofdiffuselargebcelllymphoma AT stefaniepederiva diagnosisandtreatmentofdiffuselargebcelllymphoma AT christiantaverna diagnosisandtreatmentofdiffuselargebcelllymphoma AT alexandertzankov diagnosisandtreatmentofdiffuselargebcelllymphoma AT olivermeier diagnosisandtreatmentofdiffuselargebcelllymphoma AT karenyeow diagnosisandtreatmentofdiffuselargebcelllymphoma AT christophrenner diagnosisandtreatmentofdiffuselargebcelllymphoma |